Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

Ripple-backed XRP treasury firm eyes Nasdaq debut with $1B plan

Is Jabil Stock Outperforming the S&P 500?

It's called 'private credit' — and it could lead to big trouble on Wall Street

JPMorgan cuts S&P 500 target as analysts say the domino effects from oil-price shock aren’t baked in

3 Defensive ETFs That Are Quietly Crushing the S&P 500 While Tech Implodes